Compugen Discovered Protein Shown To Abolish Recurring Relapses In Multiple Sclerosis Animal Model
Posted Jul 07 2010 12:00am
July 7, 2010 - Compugen Ltd. (NASDAQ:CGEN) announced that administration of CGEN-15001 in an animal model ofmultiple sclerosis(MS) has been shown to completely abolish spontaneous relapses. In addition, administration of this novel molecule prior to disease onset demonstrated a pronounced delay of disease onset and a significant decrease in disease symptoms. These results, together with complementary results from earlier studies, strongly support a significant potential therapeutic utility for CGEN-15001 in the treatment of multiple sclerosis and other autoimmune diseases, such as rheumatoidarthritis, systemiclupuserythematosus, inflammatory bowel disease, and type 1diabetes
CGEN-15001 is a soluble recombinant fusion protein comprised of the extracellular region of a Compugen discovered B7/CD28 family member, designated CGEN-15001T. CGEN-15001T, which itself has potential medical utilities - such as serving as a target for antibody therapeutics - was discovered by Compugen through the use of its LEADS platform and a proprietary algorithm designed to predict novel members of known protein families. Patents have been filed for both CGEN-15001 and CGEN-15001T.